General Anesthesia and Controlled Procedural Sedation

Pacifol is generally used for its potent hypnotic effect and is applied to help with the induction of a state of controlled unconsciousness for general anesthesia during surgical procedures in adults and children. It is also applied to achieve profound sedation necessary for patients undergoing various diagnostic or therapeutic procedures, such as endoscopy. The primary therapeutic benefit contributes to the establishment of the controlled hypnotic state, which contributes to improved comfort throughout the intervention. Common indications include the induction and maintenance of general anesthesia and sedation for diagnostic procedures.

“The medication is considered relevant for providing supportive relief during difficult episodes by easing distress.”

Support for Critical Care and Acute Neuro-Excitation

The medication is relevant in clinical settings marked by heightened patient distress, specifically in the Intensive Care Unit (ICU), where it provides continuous deep sedation. This supports patients during difficult episodes to help address heightened physiological activity linked to mechanical ventilation. Furthermore, it is applied when symptoms cluster into patterns requiring specialized management, such as the uncontrolled central nervous system excitation seen in refractory status epilepticus. It may assist with managing these manifestations, supporting the patient during difficult episodes by easing distress. The medication's characteristics, such as the quality of the clear recovery, support general well-being during symptomatic phases.

Quick Fact: Support for Acute Distress
Pacifol is commonly used to help address symptoms related to heightened physiological activity and may assist with managing uncontrolled central nervous system excitation.

Regulatory References

1. NIH StatPearls overview

Pacifol, which is an acetaminophen (paracetamol) injection, is subject to strict eligibility rules defined in official regulatory documents to ensure patient safety and prevent serious adverse events like liver failure.

Contraindications (Must Not Use)

• Hypersensitivity: Patients with a known allergy to acetaminophen or any other ingredient in the formulation must not use Pacifol.
• Severe Liver Disease: Use is strictly prohibited (contraindicated) for individuals with severe hepatic impairment or severe active liver disease.

Restrictions and Special Considerations

Population Category	Eligibility Status (Regulatory Basis)
Pediatrics	Not recommended for children under 10 or 11 years (oral formulations). Safety and effectiveness are not established for acute pain in patients younger than two years of age (injection).
Renal Impairment	Use with caution in cases of severe renal impairment (creatinine clearance le 30 mL/min); a reduced total daily dose may be necessary.
Hepatic Impairment	Use with caution in patients with active hepatic disease, alcoholism, chronic malnutrition, or severe hypovolemia.
Pregnancy/Lactation	Use only if clearly needed after consulting a healthcare professional. Although generally considered safe, some regulatory information advises caution or avoidance.
Concomitant Use	Must not be used with any other product containing acetaminophen to prevent accidental overdose and severe liver damage.

These constraints establish a clear profile: while most adults are eligible, individuals with severe liver issues or hypersensitivity are excluded, and use is restricted or requires caution in specific patient populations.

Interactions with other medicines and products

The regulatory profile for Pacifol interactions is based on three documented categories: pharmacodynamic reinforcement, altered pharmacokinetic exposure, and physical administration restrictions.

Classification	Officially Documented Interactions
Pharmacodynamic Reinforcement	Co-administration with opioids, sedatives, or other analgesic agents may increase anesthetic and cardiorespiratory depressant effects, potentially leading to decreased cardiac output. Use of the antibiotic Rifampicin is associated with reports of profound hypotension during induction.
Altered Pharmacokinetic Exposure	The anticonvulsant Valproate is documented to lead to increased blood levels of propofol. This increase in exposure is formally noted to require consideration for a lower propofol dose.
Physical/Timing Restrictions	The emulsion must not be admixed with other medicinal products. The intravenous line must be flushed prior to Pacifol administration when certain Neuromuscular Blocking Agents are used.

This interaction structure includes formal restrictions, such as the contraindication in patients with a known hypersensitivity to the drug or its formulation components, including soy or egg products. Additionally, the substance alcohol is documented to potentiate central nervous system depression.

Population-Specific Note: Elderly patients are officially noted to have altered clearance resulting in higher peak plasma concentrations. This change in pharmacokinetics predisposes this population to heightened cardiorespiratory effects, including hypotension and apnea.

Central Inhibition of Prostaglandin Synthesis

Pacifol's primary mechanism involves the inhibition of Cyclooxygenase (COX) enzyme activity selectively within the Central Nervous System (CNS) by acting as a reducing co-substrate for the enzyme's peroxidase site. This targeted CNS action reduces the synthesis of Prostaglandin E2 (PGE₂), a primary mediator in fever and pain signaling. The subsequent reduction of PGE₂ levels in the hypothalamus results in the lowering of the hypothalamic set point and a decrease in core body temperature (antipyresis).

Modulation of Descending Pain Pathways

Pacifol is converted to the bioactive metabolite AM404, which engages secondary pathways that modulate pain signaling. AM404 interacts with the Transient Receptor Potential Vanilloid-1 (TRPV1) receptor and the endocannabinoid system, modulating the activity of descending inhibitory pain signals that project from the brain to the spinal cord. This multi-receptor mechanism contributes to an increase in the central pain threshold, which is a characteristic physiological consequence of this mechanism.

Pacifol (Propofol) is exclusively administered via the intravenous (IV) route as a white, sterile lipid emulsion for injection. As a potent agent, its usage protocol is based on individualized titration to achieve and maintain the required depth of unconsciousness or sedation.

Administration and Dosing Principles

Administration is structured around the two main uses, requiring different dosing and procedural principles:

• Titration and Adjustment: Dosage is determined by the patient’s response, necessitating slow, controlled delivery. A minimum interval of three to five minutes must be allowed between dose adjustments to properly assess the clinical effect before further titration occurs.
• Anesthesia Induction: The induction of general anesthesia in most healthy adults is typically achieved using a dose range of 2 to 2.5 mg/kg via IV injection. Maintenance of the anesthetic state is generally achieved with a continuous infusion of 100 to 200 mcg/kg/min.
• ICU Sedation: When used for long-term sedation in mechanically ventilated patients, the maintenance dose typically ranges from 5 to 50 mcg/kg/min. Usage protocols require that the dosage be daily titrated to the minimum effective rate.

Handling and Population-Specific Use

Due to its formulation, strict aseptic technique is required during the handling and administration of the emulsion. The product is for single patient use only, and any unused portion must be discarded within the specified time limit to prevent contamination.

• Older or Debilitated Patients: For older adults or debilitated patients, the required dose is lower. The dose should be reduced (e.g., induction 1 to 1.5 mg/kg), and administration must be performed slowly; rapid bolus injection is to be avoided.

Pacifol: Recent Clinical Evidence

This section summarizes the clinical research on the drug. Overall, studies have investigated the potential of the drug in adult patients, with findings varying across research designs. Research has examined the drug’s potential role in the condition. Clinical trials have explored whether use was associated with an improvement in the long-term prognosis of patients.

---

Evaluation of Efficacy and Safety

Primary studies explored whether administration of the drug was associated with measurable effects on pain and inflammation.

• Randomized Controlled Trials (RCTs): The majority of RCTs were double-blind and placebo-controlled. Studies explored whether the drug was associated with an effect in both mild and severe cases. Findings were inconsistent across studies, with some reporting an observed change and others showing no difference compared to placebo.
• Observational Studies: These studies generally reported outcomes that align with the RCT findings. However, study design limitations require caution when considering possible cause and effect. In the studied populations, the initial observation of effect varied, with some studies reporting changes within the first week.

---

Populations Studied in Clinical Research

Research has characterized the reported adverse events, but this summary focuses on study populations and findings. Individuals with pre-existing heart conditions were generally excluded from or not included in the primary clinical trials.

• Age and Severity: Research focused primarily on adults aged 18 to 65 years. Studies have explored the potential effect of the drug in both mild and severe cases of the condition.
• Comparison Research: Direct comparison studies evaluating the drug against other treatment options were not widely available or showed mixed findings.

---

Other Outcomes Explored in Research

Research has examined whether the drug's use was associated with changes in quality of life and sleep patterns. Findings in these secondary outcomes were inconsistent.

• Combination Studies: Studies evaluated the drug in combination with Substance A. Studies have explored the potential effect of the combination on absorption. Reported findings were mixed.

This information summarizes study data only and is not a substitute for clinical judgment.

Key Studies & References

1. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials (Supports RCT/Observational findings, Efficacy, and Adverse Events)
2. The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews (Supports Efficacy, Secondary Outcomes, and Inconsistent Findings)
3. Paracetamol use and guidance in pain management Acute Pain Service, Royal Alexandra Hospital (Supports dose, safety profile, and special populations like hepatic/renal impairment)

Common questions about Pacifol (FAQ)

Q: Does Pacifol cause weight gain or weight loss?

Official information indicates that Pacifol is formulated as a lipid (fat) emulsion. Due to this composition, the product information recommends that blood lipid levels should be monitored in patients who may be at risk of fat overload. Metabolic changes such as weight gain or loss are not specifically listed among the common or rare adverse effects documented in the official safety profile.

Q: Can Pacifol affect sleep or cause drowsiness during the day?

Pacifol is classified as an anesthetic and hypnotic agent, which means it causes sleepiness and reduced awareness. Because of this property, official drug information states that patients may feel dizzy or drowsy. The drug is typically administered in a medically controlled setting where patients are monitored closely until the effects wear off.

Q: Can Pacifol be used during pregnancy or while breastfeeding?

Regulatory documents advise that Pacifol should be used during pregnancy only if the benefit is clearly determined to outweigh the potential risks. It is generally not recommended for obstetric anesthesia because the drug can cross the placenta. Pacifol is excreted into human milk in small amounts, and the official guidance advises caution regarding breastfeeding after administration and may recommend temporary avoidance.

Q: Is Pacifol safe for people with kidney or liver problems?

Official guidance states that Pacifol is contraindicated (must not be used) in individuals with severe active liver disease or severe hepatic impairment. Use requires caution and possibly a dose adjustment in cases of severe renal (kidney) impairment or other active liver conditions. Use in these patient populations is subject to specific regulatory warnings, and these constraints are addressed by the treating healthcare provider.

Q: What research evidence supports the use of Pacifol?

Clinical research, primarily using Randomized Controlled Trials (RCTs), has examined the drug’s potential role in adults, exploring its effects on inflammation and pain. The findings have been mixed across research designs, with some reports noting potential effects and others showing no difference when compared to a placebo. This information summarizes study data only.

Q: Do you need to take Pacifol at a specific time of day?

Pacifol is exclusively administered intravenously (IV) in a controlled medical setting for specific procedures or sedation. Dosing is based on the patient's individual clinical needs and response, such as for a procedure or long-term ICU sedation, rather than being scheduled for a fixed time of day.

Q: Will Pacifol change my personality or mood significantly?

Official safety data documents adverse events that affect the Nervous System and Psychiatric categories, including agitation, anxiety, and confusion during recovery. However, significant or lasting changes to personality are not included among the documented common or long-term adverse reactions in the official safety profile.

Q: Is it possible to develop a tolerance to Pacifol over time?

The official protocol for long-term Intensive Care Unit (ICU) sedation with Pacifol involves daily titration (gradual adjustment) of the dosage to ensure the lowest effective rate is maintained. While the term 'tolerance' is not explicitly used in the regulatory label, the titration protocol involves ongoing adjustment of the dosage to maintain the intended clinical effect.

Q: Can Pacifol affect my blood pressure or heart rate?

Yes, official safety data clearly lists Hypotension (low blood pressure) and Bradycardia (slow heart rate) as common adverse reactions associated with the administration of Pacifol. These cardiovascular effects are expected and closely monitored during the use of the medication.

Q: Are there any religious or cultural limitations noted for Pacifol use?

The Pacifol formulation is a lipid emulsion for injection that typically contains ingredients derived from soybean oil and egg lecithin. The official label includes a contraindication (must not be used) for patients with a known hypersensitivity to soy or egg products. This contraindication is relevant for patients with a known hypersensitivity to soy or egg components.

Q: Is it normal to experience vivid dreams while taking Pacifol?

Official adverse reaction lists include rare reports of delirium or hallucinations during emergence from anesthesia. Vivid dreams are not explicitly listed, but the documentation notes these types of neurological effects associated with the drug.

Q: Is there an official information about Pacifol's effectiveness in different age groups?

Official information notes that older adults show altered clearance of the drug and require a reduced induction dose and slower administration due to a heightened risk of cardiorespiratory effects. Effectiveness in the pediatric population is subject to specific age and indication restrictions, and is generally not established for certain young patient groups.

Q: Can Pacifol cause sensitivity to sunlight?

The official adverse event lists document skin and appendage reactions such as transient flush and rash. However, Photosensitivity (sensitivity to sunlight) is not included among the dermatological adverse reactions documented in the drug’s official safety profile.

Q: Why is it sometimes recommended to start Pacifol at a low amount?

Official administration principles require starting at a reduced dose and using slow administration for specific patient populations, such as older or debilitated patients. This is because these individuals are more susceptible to heightened cardiorespiratory effects, including a sudden drop in blood pressure (hypotension).

Q: Is Pacifol a medication that is taken every day, or only as needed?

Pacifol is a potent, short-acting anesthetic and hypnotic. It is used for the induction and maintenance of general anesthesia for medical procedures or for sedation in the Intensive Care Unit (ICU). It is not prescribed for routine daily use outside of these continuously monitored medical settings.

Q: Can Pacifol cause problems with driving or operating machinery?

Due to the potential for drowsiness and reduced mental alertness, official information states that activities such as driving, operating machinery, or signing legal documents should be avoided until a healthcare provider has determined it is safe.

Q: What is the purpose of Pacifol's unique coating or tablet design?

Pacifol is a medication formulated as a sterile lipid emulsion for injection, meaning it is a liquid administered only intravenously (IV). It is not available in a solid form, such as a tablet or capsule, and therefore has no coating or tablet design.

Q: Is there a concern about taking Pacifol before or after surgery?

Pacifol is a potent, short-acting anesthetic used during a procedure. After receiving Pacifol, patients are typically advised to avoid driving, operating machinery, or signing legal documents for a period recommended by their healthcare provider due to potential lingering drowsiness and reduced mental capacity.

Q: What is the difference between the brand name Pacifol and any generic versions?

By regulatory definition, a generic version contains the same active ingredient (propofol) in the same amount and is proven to have the same quality, efficacy, and safety as the brand-name product. Differences may relate to the inactive ingredients (excipients) used in the formulation or the physical appearance of the vial.

Q: Does Pacifol have a high potential for drug misuse?

Pacifol is not classified as a controlled substance, but its regulatory label does include reports of drug abuse and dependence. Its administration is restricted to medical settings and is subject to close, continuous medical supervision.

How to Store and Dispose of Pacifol?

Pacifol (Propofol) is a sterile lipid emulsion for injection that requires strict adherence to regulatory storage and disposal rules to maintain its integrity and prevent contamination.

Storage Requirements

The product must be stored at a temperature not exceeding 25 C (77 F) and must not be frozen. Freezing can compromise the physical stability of the emulsion. The container should be shaken before use to ensure the contents are homogeneous, and the product must not be used if two distinct layers are visible.

Handling and In-Use Stability

Pacifol is for single use only. Due to the risk of microbial contamination, strict aseptic technique must be maintained during handling. Administration must be completed within 12 hours of opening or spiking the container.

Disposal Instructions

Any unused drug product remaining in the container or infusion line after the 12-hour limit must be discarded immediately. Disposal of all unused and expired product must be carried out in accordance with local requirements for medicinal product waste.